RxDoctor Payments Data

Bryan Crenshaw, MD

Family Medicine · Saraland, ALNPI 1669634796

Payments from drug & device makers

$5,740in general payments, 2019–2025

Across 506 payments — averaging $11.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$902
  • Pfizer$354
  • Amgen$335
  • AstraZeneca$270
  • Novartis$253
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,740 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$48,713
Medicare patients
157
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$46,704
FarxigaDapagliflozin Propanediol37$44,466
JanuviaSitagliptin Phosphate36$40,144
EliquisApixaban48$30,602
MounjaroTirzepatide21$28,656
TrulicityDulaglutide27$27,041
LinzessLinaclotide22$20,173
JardianceEmpagliflozin14$14,600
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,949
XareltoRivaroxaban14$8,432
VascepaIcosapent Ethyl19$7,624
MyrbetriqMirabegron14$7,115
BelsomraSuvorexant11$4,920
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$3,333
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm13$2,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$192$58,50261 claims
Novo NordiskOzempic$902$46,70443 claims
MerckJanuvia, Belsomra$60$45,06447 claims
AstraZenecaFarxiga$270$44,46637 claims
PfizerEliquis$354$30,60248 claims
AbbVieLinzess$1,399$20,17322 claims
Boehringer IngelheimJardiance$12$14,60014 claims
GSKTrelegy Ellipta$45$12,94914 claims
Johnson & JohnsonXarelto$205$8,43214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Saraland

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →